Literature DB >> 8640845

Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility-complex-negative human tumour: neuroblastoma.

P Facchetti1, I Prigione, F Ghiotto, P Tasso, A Garaventa, V Pistoia.   

Abstract

Neuroblastoma (NB) is a major-histocompatibility-complex(MHC)-negative neuroectodermal tumour that is often infiltrated with lymphocytes. A detailed characterization of NB-associated tumour-infiltrating lymphocytes (TIL) has never been carried out. Here we have investigated the immunophenotype and the cytotoxic activities of TIL from nine and seven NB patients respectively. Furthermore, the T cell receptor (TcR) variability and the patterns of cytokine gene expression of fresh versus recombinant (r) interleukin (IL)-2-cultured TIL were studied in four NB cases. The results obtained showed the following: (1) freshly isolated TIL were comprised of a mixture of CD4+ and CD8+ T cells partially expressing HLA-DR and/or CD25. The CD4/CD8 ratio ranged from 0.5 to 5 in the different cases. Upon culture of TIL with rIL-2, an increased proportion of CD56+ and CD8+ lymphocytes was consistently observed; (2) IL-2-expanded TIL lysed natural-killer(NK)sensitive and lymphokine-activated-killer(LAK)-sensitive target cell lines; (3) reverse-transcriptase/polymerase-chain-reaction (RT-PCR) experiments showed that most TcR V beta genes were expressed both in fresh and in cultured TIL, suggesting that such cell populations were polyclonal; (4) interferon gamma, IL-4, IL-5, tumour necrosis factor (TNF) alpha, IL-8, IL-10 mRNA and, to a lesser extent, IL-2 mRNA were expressed by cultured TIL, as assessed by RT-PCR; the corresponding tumour samples consistently contained TNF alpha, IL-8 and IL-10 mRNA, whereas IL-2 and IFN gamma mRNA were faintly expressed in some NB tumours and IL-4 and IL-5 mRNA were never detected. A total of 90 clones were subsequently raised from IL-2-expanded TIL from six NB patients; 87/90 clones were of T cell lineage with a CD4+ or CD8+ immunophenotype, whereas the 3 remaining clones were of NK cell origin. Upon triggering of the CD3-TcR complex, 64% CD4+ and 77% CD8+ T cell clones killed the murine P815 mastocytoma cell line. Virtually no T cell clone lysed a LAK-sensitive NB cell line whereas 15% CD4+ and 17% CD8+ clones mediated NK-like activity against the K562 cell line. Finally, the patterns of cytokine production by CD4+ clones were roughly consistent with those of a T helper (TH) 1 profile and similar to those observed in CD8+ clones.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640845     DOI: 10.1007/s002620050267

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  15 in total

Review 1.  Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans.

Authors:  Leonid S Metelitsa
Journal:  Clin Immunol       Date:  2010-11-20       Impact factor: 3.969

2.  Ets1 transcription factor mediates gastrin-releasing peptide-induced IL-8 regulation in neuroblastoma cells.

Authors:  Jingbo Qiao; Jung-Hee Kang; Jeremy Cree; B Mark Evers; Dai H Chung
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

3.  Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma.

Authors:  Marco Mina; Renata Boldrini; Arianna Citti; Paolo Romania; Valerio D'Alicandro; Maretta De Ioris; Aurora Castellano; Cesare Furlanello; Franco Locatelli; Doriana Fruci
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

4.  Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.

Authors:  Liping Song; Shahab Asgharzadeh; Jill Salo; Kelly Engell; Hong-wei Wu; Richard Sposto; Tasnim Ara; Ayaka M Silverman; Yves A DeClerck; Robert C Seeger; Leonid S Metelitsa
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

5.  Invariant natural killer T infiltration in neuroblastoma with favorable outcome.

Authors:  Tomoro Hishiki; Naoko Mise; Kazuaki Harada; Fumie Ihara; Mariko Takami; Takeshi Saito; Keita Terui; Mitsuyuki Nakata; Shugo Komatsu; Hideo Yoshida; Shinichiro Motohashi
Journal:  Pediatr Surg Int       Date:  2017-10-10       Impact factor: 1.827

6.  The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes.

Authors:  Lena-Maria Carlson; Anna De Geer; Baldur Sveinbjørnsson; Abiel Orrego; Tommy Martinsson; Per Kogner; Jelena Levitskaya
Journal:  Oncoimmunology       Date:  2013-03-01       Impact factor: 8.110

7.  Immunosuppressive microenvironment in neuroblastoma.

Authors:  Vito Pistoia; Fabio Morandi; Giovanna Bianchi; Annalisa Pezzolo; Ignazia Prigione; Lizzia Raffaghello
Journal:  Front Oncol       Date:  2013-06-26       Impact factor: 6.244

8.  Expression of FOXP3, CD14, and ARG1 in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival.

Authors:  Sara Stigliani; Michela Croce; Fabio Morandi; Paola Scaruffi; Valentina Rigo; Barbara Carlini; Carla Manzitti; Anna Rita Gigliotti; Gian Paolo Tonini; Vito Pistoia; Silvano Ferrini; Maria Valeria Corrias
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

9.  Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2.

Authors:  Leonid S Metelitsa; Hong-Wei Wu; Hong Wang; Yujun Yang; Zamir Warsi; Shahab Asgharzadeh; Susan Groshen; S Brian Wilson; Robert C Seeger
Journal:  J Exp Med       Date:  2004-05-03       Impact factor: 14.307

10.  Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma.

Authors:  Lotte Spel; Jaap-Jan Boelens; Dirk M van der Steen; Nina J G Blokland; Max M van Noesel; Jan J Molenaar; Mirjam H M Heemskerk; Marianne Boes; Stefan Nierkens
Journal:  Oncotarget       Date:  2015-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.